SCHEMBL2369273

SCHEMBL2369273

CC1(C)OC(=O)N[C@@H]1Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.42
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
TSHR P16473 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 2/20 0.38
HTT P42858 2/20 0.38
ABCB1 P08183 1/20 0.37
HDAC8 Q9BY41 2/20 0.37
TLR9 Q9NR96 1/20 0.37
CA2 P00918 1/20 0.37
MAOB P27338 1/20 0.37
ELANE P08246 1/20 0.37
CTSG P08311 1/20 0.37
PRTN3 P24158 1/20 0.37
PLA2G10 O15496 1/20 0.37
PLA2G5 P39877 1/20 0.37
EP300 Q09472 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL531693 1.00 LMNA (0.42) LMNADDB1CRBNNPSR1TSHR
SCHEMBL531694 1.00 LMNA (0.42) LMNADDB1CRBNNPSR1TSHR
SCHEMBL8926068 0.80 CA2 (0.37) LMNADDB1CRBNNPSR1TSHR
SCHEMBL31403360 0.79 HDAC8 (0.36) DDB1CRBNTSHRHTTHDAC8
SCHEMBL5872462 0.79 HDAC8 (0.36) DDB1CRBNTSHRHTTHDAC8
SCHEMBL5872468 0.79 HDAC8 (0.36) DDB1CRBNTSHRHTTHDAC8
SCHEMBL13949518 0.78 LMNA (0.38) LMNADDB1CRBNNPSR1TP53
SCHEMBL11365386 0.74 GBA1 (0.41) LMNADDB1CRBNTSHRHTT
SCHEMBL2366727 0.74 CA2 (0.42) LMNACA2
SCHEMBL1443388 0.74 CA2 (0.42) LMNACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112204018-B Acrylic compound, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2023-08-29 CN disclosed
CN-112204018-A Acrylic acid compounds, preparation method thereof, pharmaceutical composition and application 中国科学院上海药物研究所 2021-01-08 CN disclosed
US-8017779-B2 Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-09-13 US disclosed
US-20070213356-A1 Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213356-A1 Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines IL2, IFNG, IRF3 LMNA 3850/4885DDB1 1439/4885CRBN 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.